GLP-3-R (Glucagon-Like Peptide Analog — Triple Receptor Agonist)
Also Known AsGLP-3R · Triple GLP Agonist · GLP-1/GIP/GCG Triagonist
GLP-3-R refers to a class of engineered glucagon-like peptide analogs designed to activate three receptors simultaneously: GLP-1R, GIPR, and GCGR (glucagon receptor). The triagonist approach was pioneered by Richard DiMarchi and colleagues at Indiana University, with the rationale that co-activation of all three incretin and glucagon pathways produces synergistic metabolic benefits exceeding single- or dual-agonist strategies. Retatrutide (LY3437943, Eli Lilly) is the most advanced clinical triagonist in this class.
How GLP-3-R Works
GLP-1 Receptor Agonism
Activation of GLP-1R on pancreatic beta cells stimulates glucose-dependent insulin secretion and suppresses glucagon. GLP-1R activation in the hypothalamus and brainstem reduces appetite and food intake. GLP-1R signaling in the GI tract slows gastric emptying, prolonging satiety.
GIP Receptor Agonism
Glucose-dependent insulinotropic polypeptide receptor (GIPR) activation complements GLP-1R signaling by enhancing insulin secretion, improving beta-cell function, and promoting lipid metabolism in adipose tissue. GIPR co-agonism may also amplify central appetite suppression and improve GLP-1R agonist tolerability.
Glucagon Receptor Agonism
GCGR activation increases hepatic glucose output acutely but also drives energy expenditure through hepatic FGF21 secretion, amino acid catabolism, and brown adipose tissue thermogenesis. The energy expenditure component complements the appetite suppression of GLP-1R/GIPR co-agonism, accelerating fat mass loss.
Synergistic Metabolic Integration
The triple-agonist design exploits complementary metabolic effects: GLP-1R and GIPR drive appetite suppression and insulin secretion, while GCGR drives energy expenditure and lipid oxidation. The glucagon-mediated hyperglycemic effect is counterbalanced by the insulinotropic GLP-1R and GIPR activity, resulting in net glycemic improvement with enhanced weight loss.
Published Research
Obesity & Weight Management
StrongPhase II clinical data for retatrutide (the most advanced triagonist) demonstrated up to 24.2% mean body weight reduction at 48 weeks — the largest weight loss observed for any anti-obesity pharmacotherapy. The triagonist approach consistently exceeds weight loss achieved by single (GLP-1R, e.g., semaglutide) and dual (GLP-1R/GIPR, e.g., tirzepatide) agonists.
Type 2 Diabetes & Glycemic Control
StrongTriagonists demonstrate robust HbA1c reductions, with clinical data showing mean reductions exceeding 2.0% from baseline. The triple mechanism provides complementary glycemic control: GLP-1R and GIPR enhance insulin secretion while GCGR-stimulated hepatic glucose output is counterbalanced by the net insulinotropic effect.
Non-Alcoholic Steatohepatitis (NASH/MASH)
ModerateGCGR agonism drives hepatic lipid oxidation and FGF21-mediated reduction of hepatic steatosis. Clinical data from triagonist studies show significant reductions in liver fat content (measured by MRI-PDFF), positioning the triagonist class as potentially disease-modifying for metabolic-associated steatotic liver disease.
Cardiovascular Risk Reduction
EmergingSecondary cardiovascular endpoints in clinical trials demonstrate improvements in systolic blood pressure, LDL cholesterol, triglycerides, and inflammatory markers (hs-CRP). Whether the triagonist class provides cardiovascular mortality benefit (as demonstrated for semaglutide in SELECT) requires dedicated outcomes trials.
Obstructive Sleep Apnea
EmergingThe magnitude of weight loss achieved with triagonists (>20%) may be sufficient to resolve or significantly improve obstructive sleep apnea, as demonstrated in incretin agonist studies showing reduced apnea-hypopnea index (AHI) proportional to weight loss. Dedicated OSA endpoint trials for triagonists are anticipated.
Safety Profile
The safety profile of triple agonists mirrors the incretin class: nausea, vomiting, diarrhea, and constipation are the most common adverse events, primarily during dose titration. Incidence and severity are generally comparable to dual agonists (tirzepatide). Hypoglycemia incidence is low when used without sulfonylureas or insulin. GCGR agonism requires monitoring for hepatic transaminase elevation and lean mass preservation during rapid weight loss.
Handling & Storage
Reconstitute with bacteriostatic water. Direct gentle stream along vial wall — do not shake. Store reconstituted solution at 2-8°C and use within 30 days. Lyophilized powder stable at -20°C for 24+ months. Protect from excessive heat during shipping.
Peer-Reviewed Literature
- 1
Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial
Jastreboff AM, Kaplan LM, Frías JP, et al.
- 2
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial conducted in the USA
Rosenstock J, Frias J, Jastreboff AM, et al.
- 3
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan B, Yang B, Ottaway N, et al.
- 4
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept
Coskun T, Urva S, Roell WC, et al.
GLP-3-R FAQ
What is GLP-3-R?
GLP-3-R refers to a triple receptor agonist class that simultaneously activates GLP-1, GIP, and glucagon receptors. By engaging all three receptors, these molecules produce synergistic effects on appetite suppression (GLP-1R/GIPR), insulin secretion (GLP-1R/GIPR), and energy expenditure (GCGR), resulting in greater weight loss than single- or dual-agonist approaches.
How does a triple agonist compare to semaglutide?
Semaglutide is a selective GLP-1R agonist producing approximately 15-17% weight loss. Tirzepatide (dual GLP-1R/GIPR agonist) achieves approximately 20-22%. Triple agonists like retatrutide have demonstrated up to 24.2% weight loss in phase II trials. The incremental benefit comes from glucagon receptor-mediated energy expenditure on top of incretin-mediated appetite suppression.
What role does glucagon receptor activation play?
Glucagon receptor (GCGR) activation increases energy expenditure through hepatic FGF21 secretion, brown adipose tissue thermogenesis, and amino acid catabolism. While glucagon alone would raise blood glucose, the simultaneous GLP-1R and GIPR agonism provides sufficient insulinotropic counterbalance, resulting in net glycemic improvement with enhanced fat loss.
What is the purity of G26x Peptides GLP-3-R?
Our GLP-3-R is 99%+ purity, independently verified by Janoshik Analytical with a full Certificate of Analysis (COA) available for each batch. It is supplied as a lyophilized powder manufactured under GMP-adjacent conditions.
How should GLP-3-R be stored?
Lyophilized GLP-3-R should be stored at -20°C for long-term storage (stable for 24+ months). Once reconstituted with bacteriostatic water, store at 2-8°C and use within 30 days. Protect from excessive heat during shipping and storage.
GLP-3-R Products
All compounds 99%+ purity, verified by Janoshik Analytical. GMP-manufactured lyophilized powder.
GLP-3 R
10mgNext-gen metabolic research beyond semaglutide — targets novel receptor pathways in the incretin system for advanced metabolic studies.
- Next-generation metabolic signaling beyond GLP-1
- Advanced incretin biology research compound
Explore Related Research
AOD 9604
5mgThe fat-burning fragment of growth hormone — targets and destroys stubborn body fat (especially belly fat) without touching muscle, blood sugar, or hormone levels.
- Burns fat without affecting blood sugar or growth hormone levels
- Targets stubborn belly fat specifically
Disclaimer: This monograph is provided for educational and research purposes only. G26x Peptides products are sold exclusively as research chemicals. They are not intended for human consumption, therapeutic use, or as dietary supplements. All research should be conducted in compliance with applicable laws and institutional review board protocols. Information presented here is sourced from published peer-reviewed literature and does not constitute medical advice.